FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Beatrice Mohelnikova-Duchonova, Bohuslav Melichar, Pavel Soucek
https://pubmed.ncbi.nlm.nih.gov/25132748/Actively Recruiting
Led by The Methodist Hospital Research Institute · Updated on 2026-10-07
57
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of combining 5-FluorouracilLeucovorin 5FULV with regorafenib for adults with metastatic colorectal cancer who have already tried two prior treatments. This randomized phase II trial compares this combination to a control treatment of trifluridine-tipiracil plus bevacizumab to understand if the new combination is not worse than the current option. The study aims to provide insights in the third-line treatment setting for this advanced cancer. Participants are randomly assigned in a 21 ratio to one of two treatment groups. The experimental group receives 5FULV given intravenously in 2-week cycles along with regorafenib taken orally with dose escalation weekly, following a 3-weeks-on1-week-off schedule, for up to 12 cycles or until disease progression or unacceptable side effects. The control group is given oral trifluridine-tipiracil twice daily on specified days in a 28-day cycle, combined with intravenous bevacizumab on days 1 and 15, repeated until progression, toxicity, or consent withdrawal, also up to 12 cycles. Throughout the study, participants undergo regular assessments to monitor treatment effects and side effects. Researchers measure how long the treatment controls the cancer, progression-free survival, response duration, and safety. Evaluations include clinical exams, laboratory tests, and monitoring for any adverse events. The study duration and follow-up extend up to 18 months to capture these outcomes and ensure participant safety and well-being during and after treatment.
CONDITIONS
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
S
Safiya Joseph
T
Titilayo Olubajo
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Methodist Hospital Research Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 5‑fluorouracil/leucovorin + regorafenib | Trifluridine‑tipiracil + bevacizumab |
|---|---|---|
| What it is | Combination chemotherapy of 5‑fluorouracil/leucovorin with regorafenib given in third‑line metastatic colorectal cancer | Oral trifluridine‑tipiracil with bevacizumab as third‑line therapy for metastatic colorectal cancer |
| Primary use | Being assessed as a potential third‑line treatment option | Used as an active comparator third‑line treatment option |
| Evidence status beyond this trial | Limited evidence currently exists for this exact combination; regorafenib alone is modestly effective in refractory metastatic CRC but combining with 5‑FU/LV is investigational | Trifluridine‑tipiracil plus bevacizumab improved overall survival versus trifluridine‑tipiracil alone in third‑line setting |
| Important limitations | Safety and efficacy of the combination are not yet established in randomized trials | Benefit shown versus TAS‑102 alone but hematologic toxicity remains a concern |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 treatment cycles
Participants receive either 5FU/LV with regorafenib or trifluridine-tipiracil plus bevacizumab according to their assigned group. Treatment continues in cycles up to 12 cycles or until disease progression, unacceptable toxicity, or withdrawal of consent.
Visits every 2 weeks or every 4 weeks depending on treatment arm
Duration - Up to 18 months
Participants are monitored for treatment outcomes including cancer progression, response duration, and safety for up to 18 months after starting treatment.
Regular follow-up visits as scheduled by the study team
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Beatrice Mohelnikova-Duchonova, Bohuslav Melichar, Pavel Soucek
https://pubmed.ncbi.nlm.nih.gov/25132748/Napoleone Ferrara
https://pubmed.ncbi.nlm.nih.gov/12360282/Emaan Haque, Ibrahim N Muhsen, Abdullah Esmail...
https://pubmed.ncbi.nlm.nih.gov/36620581/Nordic Gastrointestinal Tumor Adjuvant Therapy Group
https://pubmed.ncbi.nlm.nih.gov/1588370/Gabriele Bergers, Steven Song, Nicole Meyer-Morse...
https://pubmed.ncbi.nlm.nih.gov/12727920/George D Demetri, Peter Reichardt, Yoon-Koo Kang...
https://pubmed.ncbi.nlm.nih.gov/23177515/Gerald W Prager, Julien Taieb, Marwan Fakih...
https://pubmed.ncbi.nlm.nih.gov/37133585/Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki...
https://pubmed.ncbi.nlm.nih.gov/28760399/Tejaswini Parlapalle Reddy, Usman Khan, Ethan Alexander Burns...
https://pubmed.ncbi.nlm.nih.gov/33312889/Axel Grothey, Eric Van Cutsem, Alberto Sobrero...
https://pubmed.ncbi.nlm.nih.gov/23177514/The Methodist Hospital Research Institute
Lead Sponsor